Frontotemporal Dementia Drug Discovery Program
The Alzheimers Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Dementias (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this Request for Proposals (RFP).
Research investigating the pathologic mechanisms of neurodegeneration in frontotemporal dementia (FTD) and related disorders has advanced recently, creating new potential targets for drug discovery.
Examples of programs appropriate for this RFP include, but are not limited to:
Target validation studies
Development and testing of novel high throughput screening assays
Medicinal chemistry on lead compounds
Identification and in vitro testing of potentially disease modifying lead compounds
Testing of lead compounds in a relevant animal model for preclinical proof of concept
ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds
Development and testing of targeted gene delivery strategies
Development of biomarkers to accelerate drug development and early diagnosis
